PDCD1 and glioblastoma: These two investigations indicate that neoadjuvant anti-PD-1 therapy may trigger an enhanced local and systemic immune response and significantly improve the median OS and PFS when compared with adjuvant therapy alone, thus acting as a more efficient approach for GBM therapy [107].